Molecular breast cancer subtypes and therapies in a public hospital of Northeastern Brazil

Andrade, Ana Cláudia de; Júnior, Carlos Alberis Ferreira; Guimarães, Beatriz Dantas; Barros, Ana Waleska Pessôa; Almeida, Gibran Sarmento de; Weller, Mathias

doi:10.1186/1472-6874-14-110

Cited by 30 publications

(22 citation statements)

References 44 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The immunostaining results of ER, PR and Her-2/neu in this study are in agreement with similar recent studies (Andrade et al, 2014;Elesawy et al, 2014). However a variable difference does exist with others (Bhargava et al, 2009;Cheang et al, 2009).…”

Section: Discussionsupporting

confidence: 93%

“…We found triple negative more common in younger age group in keeping with studies from Netherland (Kruijf et al, 2014). In contrast a study from Brazil found significantly increased rates of triple negative tumors, in patients above 50 years age (Andrade et al, 2014). Thus there are wide variations from different regions and populations with regards to the prevalence of the molecular subtypes, probably due to genetic reasons or methodology of studies and calculation.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation

Elkablawy

Albasry²,

Hussainy³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 86%

Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation

Elkablawy

Albasry²,

Hussainy³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Genetic studies associated with studies on the clinical progression of breast cancer have shown that prognosis is better with the luminal A subtype compared to the other subtypes . According to the usual immunohistochemical classification, this subtype accounts for around 60% of cases of breast carcinoma , a proportion that is similar to that found in the present sample (58.1%). With the usual immunohistochemical classification model, luminal A tumors are defined as those that are positive for the hormone receptors (estrogen and/or progesterone receptor‐positive) and negative for HER2 overexpression.…”

Section: Discussionsupporting

confidence: 65%

Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma

et al. 2015

View full text Add to dashboard Cite

It has recently been proposed to include an immunohistochemical marker of cell proliferation, Ki-67, as an element with which to classify the molecular subtypes of breast cancer. The objective of this study was to evaluate the effect of the introduction of the Ki-67 marker on the molecular classification of breast cancer by immunohistochemistry. This study was performed on 234 cases of invasive ductal carcinoma of the breast submitted to two immunohistochemical classification panels, one including Ki-67 and the other not. The data obtained with the two classifications were correlated with well-established prognostic factors such as histologic grade, the number of lymph nodes affected and tumor size. The molecular classification without Ki-67 identified: 136 cases of luminal A (58.1%), 19 cases of luminal B (8.1%), 27 cases of human epidermal growth-factor receptor 2 overexpressing (11.5%), 27 cases of basal-like (11.5%), and 25 cases of nonbasal-like triple-negative tumors (10.7%). When Ki-67 was included, this situation changed significantly, with the following cases being identified: 72 cases of luminal A (30.8%) and 83 cases of luminal B tumors (35.5%), resulting in a Kappa score of 0.216. Evaluation of correlations between the luminal A and luminal B tumor subtypes and the selected prognostic factors showed a statistically significant difference only when Ki-67 was included and only with respect to histologic grade (p < 0.001). The new classification with Ki-67 significantly altered the prevalence of the luminal A and luminal B subtypes and improved correlation with the histologic grade.

show abstract

“…16 Likewise, a group from the Northeast region of Brazil reported that nearly 50% of 633 patients with invasive breast cancer had HER-2-positive tumors by IHC. 17 The relevance of these findings is still unclear, and whether they represent underlying biological phenomena or simply the play of chance remains to be investigated. The lower number of samples from the North and Midwest regions as compared with the other three regions is one limitation of the current study.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, only a few studies have been conducted in Brazil, most of which relatively small in size or retrospective in nature. [16][17][18] In the current study, we prospectively attempted to investigate the frequency of HER-2-positive breast cancer in a large sample of Brazilian women, along with the standardization of preanalytic procedures used in the assessment of HER-2 and the association between HER-2 status and various tumor and patient features, including geographic location.…”

Section: Introductionmentioning

confidence: 99%

Assessment of HER-2 status in invasive breast cancer in Brazil

Arias

Gobbi

Ioshii

et al. 2017

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Objective: To characterize the frequency of HER-2-positive breast cancer in Brazil. Method: In this prospective observational study, we first ascertained the HER-2 status of invasive breast cancer specimens by automated immunohistochemistry (IHC). For specimens classified as 2+ by IHC, we performed in situ hybridization (ISH). Results: From February, 2011 to December, 2012, 1,495 breast specimens were registered, and 1,310 samples collected at 24 centers were analyzed. Median patient age was 54 years, and the majority of samples were obtained from segmental (46.9%) or radical mastectomy (34.4%). The predominant histological type was invasive breast carcinoma of no special type (85%), 64.3% had tubule formation (grade 3), and estrogen/progesterone receptors (ER/PR) were positive in 77.4/67.8% of the specimens analyzed, respectively. Using IHC, we found a negative HER-2 status (0 or 1+) in 72.2% of specimens, and 3+ in 18.5%; the 9.3% scored as 2+ were further analyzed by ISH, of which 15.7% were positive (thus, 20.0% of samples were HER-2--positive by either method). We found no association between HER-2 scores and menopausal status or histological type. Tumors classified as 3+ came from younger patients, and had higher histological grade and less frequent expression of ER/PR. In the North region of Brazil, 34.7% of samples were 3+, with lower frequencies in the other four regions of the country. Conclusion: Our findings provide estimates for the frequency of HER-2 positivity in Brazil and raise the hypothesis that biological differences may underlie the different distribution of breast-cancer phenotypes among different Brazilian regions.

show abstract

Molecular breast cancer subtypes and therapies in a public hospital of Northeastern Brazil

Cited by 30 publications

References 44 publications

Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation

Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation

Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma

Assessment of HER-2 status in invasive breast cancer in Brazil

Contact Info

Product

Resources

About